EN / 中文

Company Profile

Company Profile

About YZYMED

Founded in July 2011, with personalized diagnosis and treatment of cardiovascular, tumor as the strategic direction, Wuhan YZY Medical Science and Technology Co., Ltd. (YZY Med)is a high-tech enterprise specializing in the R&D, production and sales of individualized medical diagnostic products. The company has established various technical platforms, including ARMS fluorescence quantitative PCR, multiple fluorescence quantitative PCR, nucleic acid mass spectrometry, fluorescence in situ hybridization(FISH) and circulating tumor cell detection, etc. Meanwhile, the  self-developed products include molecular diagnostic products to guide personalized medicine for cardiovascular and cerebrovascular diseases, companion diagnostic products to guide tumor diagnosis and treatment, FISH products and circulating tumor cell (CTC) Autoanalyzer System, all these provide clinical diagnosis basis for precision medicine.The company has successfully developed over 160 genetic diagnostic products and multiple in vitro diagnostic (IVD) devices since 2014, among which 14 molecular diagnostic kits have obtained Medical Device Registration Certificates in Class III by National Medical Products Administration (NMPA) in China.

The company has won the following honorary awards: Hi-tech Enterprise, National Demonstration Center for Genetic Testing Technology Application, Hubei Demonstration Construction Enterprise on Intellectual Property , Specialized and New  "Little Giant" Enterprise in Hubei Province, the third batch of Invisible Champion Cultivation Enterprises in the Subdivision Field of Pillar Industries in Hubei Province, "Enterprise Research and Development Center " in Wuhan, the first batch of Supported Enterprises for "1,000 Great Enterprises and 10, 000 Innovative Talents " Program, "Golden Seed" backup stock listed enterprise, annual “Gazelle Enterprise"  from 2016 to 2021 in the East Lake Hi-tech Development Zone, Wuhan, the 1st prize of Science and Technology Progress Award in Shandong Province and Hubei Province, the second prize of China Medical Science and Technology Award in 2021.

With a  R&D center of 2,000㎡and GMP-accredited industrialized workshop of 3,200㎡, YZY Med obtained the Medical Device Production Licence" issued by Hubei Food and Drug Administration, and passed the standard attestation of ISO13485:2016.The following innovative products has passed the European Union (CE) certification: 14 kinds of genetic detection kits on cardiovascular pharmacogenome and tumor-targeted companion diagnosis.

Business Achievement

Business Achievement

The company attaches great importance on innovation and R&D, over 90 patents have been applied for and over 60 patents have been granted. The R&D team consists of over 60 people, many of whom have industrial working experience in overseas or well-known companies. The company's products have accessed into over 600 large and medium-sized hospitals in China with good market feedback, therefore established an industry position in the field of personalized medicine.

Adhering to the mission of “The right drug for the right patient”, YZY Med strives to become a leading enterprise in the field of personalized diagnosis and treatment.